Vigonvita Life Sciences Co., Ltd. Class H

As of December 31, 2025, Vigonvita Life Sciences Co., Ltd. Class H carries a market capitalization of 13.72B, placing it among publicly traded companies globally. Its enterprise value stands at 13.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Vigonvita Life Sciences Co., Ltd. Class H has 167.60M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 109.97, and the price-to-book ratio stands at 27.62.

These figures are as of December 31, 2025. The EV/Sales ratio of 121.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.85B versus a market cap of 13.72B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Vigonvita Life Sciences Co., Ltd. Class H maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 148.40, indicating elevated leverage, while an interest coverage ratio of -22.64 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Vigonvita Life Sciences Co., Ltd. Class H recorded 229,255.50 in income tax expense. The company reported a pretax loss of -397.20M and -395.88M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 86.55, while the 200-day moving average is 85.98.

Over the twelve months ended December 31, 2025, Vigonvita Life Sciences Co., Ltd. Class H generated 113.62M in revenue and converted that into -395.88M in net income, yielding earnings per share of -2.60. EBITDA reached -336.58M, while operating income came in at -350.77M.

As of December 31, 2025, Vigonvita Life Sciences Co., Ltd. Class H holds 575.85M in cash and equivalents against 719.57M in total debt, resulting in a net debt position of 169.15M. Total book value stands at 496.60M, with working capital of 41.26M providing operational flexibility.

Vigonvita Life Sciences Co., Ltd. Class H produced -107.59M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -182.29M in capital expenditures, free cash flow totaled -289.88M - equivalent to -1.90 per share.

Over the twelve months ended December 31, 2025, Vigonvita Life Sciences Co., Ltd. Class H posted a gross margin of 79.02, reflecting its pricing power and cost economics. The operating margin of -308.72 and net profit margin of -348.42 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -2.32: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.36, meaning Vigonvita Life Sciences Co., Ltd. Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Vigonvita Life Sciences Co., Ltd. Class H has an Altman Z-Score of 7.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.